Chargement en cours...
Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa‐associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are...
Enregistré dans:
| Publié dans: | Hematol Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899635/ https://ncbi.nlm.nih.gov/pubmed/31283840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hon.2647 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|